Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis
Not yet recruitingNot applicableNCT07403890
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Despite advances in immunomodulatory therapies, many Psoriatic arthritis (PsA) patients experience persistent pain unrelated to clinical active joint inflammation. Recent evidence suggests the Inferior Parietal Lobule (IPL) serves as a neuroimmune hub linking central neural activity with peripheral immune dysregulation. In a prior feasibility study, a single L-IPL-targeted TMS session reduced pain and altered immune signalling in inflammatory arthritis by reducing STAT3 phosphorylation in circulating monocytes. This study builds on those findings by evaluating whether rTMS over 4 weeks can induce sustained immune reprogramming while providing meaningful pain relief.
Study details
- Official title
- Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- Interventions
- Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS)
- Device: Control Repetitive Transcranial Magnetic Stimulation (rTMS)
- Sponsor
- NHS Greater Glasgow and Clyde
- Collaborators
- Chief Scientist Office of the Scottish Government
- Start date
- 2026-03-01
- Primary completion
- 2028-03-28
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adults ≥ 18 years ≤ 75 years * Diagnosis of PsA according to CASPAR (Classification Criteria for Psoriatic Arthritis). * Low disease activity (no more than one joint with clinically active swelling) or remission * Chronic pain for at least 3 months and VAS (Visual Analogue Scale) pain ≥30 mm * Stable treatment ≥3 months prior to entering the study * Able and willing to maintain medication for the duration study * Able to undergo MRI and TMS procedures Exclusion Criteria: * Inability to provide written informed consent. * Severe physical impairment (e.g. blindness, deafness, paraplegia) Pregnant, planning pregnancy or breast feeding. * Severe claustrophobia precluding MRI. * Contraindications to MRI (e.g. metal implants/ pacemaker). * Contraindications to TMS (e.g. history of seizures). * Serious infection including sepsis, tuberculosis and opportunistic infections such as invasive fungal infections. * Major confounding neurological disease including Multiple * Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, Alzheimer's Disease
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07403890